Fig. 6: Improvement in fertility by Ab4B19 in Cy-POF model.

a Regulation of AMH expression by Cyclophosphamide and Ab4B19 in the mouse ovary. Cy-POF mice were treated with Ab4B19 as shown in Fig. 5a. The lysates of ovarian tissues from three groups, control (Ctrl), Cy-POF mice treated with or without Ab4B19 (saline solution, or normal IgG, Ab4B19) were processed for Western blotting to detect the expression of AMH. b Quantification of AMH expression levels (ratio to β-actin). The levels of the control group were normalized to 1. N = 5 mice per group. Levels of FSH (c) and estradiol (E2) (d) were measured by ELISA from the sera collected from the three groups. (N = 6 mice per group). e Representative photomicrographs of oocytes from the three groups. Note that there were more abnormal oocytes in Cy-POF (vehicle) group than the control group, and treatment with Ab4B19 rescued the deficit. Black arrow: abnormal oocytes. Scale bar, 150 μm. f Quantification of the ovulated oocytes per mouse in each treatment group. (N = 5 mice per group). g Abnormal oocytes. The percentage of abnormal oocytes/total ovulated oocytes per mouse was calculated for each treatment group. (N = 5 mice per group). h Mean litter size in the first round of mating in control, vehicle, or Ab4B19-treated groups within 4 weeks after the administration with Ab4B19 or normal IgG (N = 6 mice per group). i Mean litter size in the second round of mating, measured for the same female mice ~5 weeks after the first-round parturition (N = 6 mice per group). Data were all presented as mean ± SEM. Statistical analyses were carried out using one-way ANOVA followed by the Dunnett’s multiple comparisons test (b–d, f–i) (*P < 0.05; **P < 0.01; ***P < 0.001). Source data are provided as a Source Data file.